A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR

Medicine & Life Sciences

1. Castration 100%
2. Prostatic Neoplasms 82%
3. Radiotherapy 72%
4. Choline 46%
5. Immunity 29%
6. Survival 16%
7. Ipilimumab 10%
8. Neoplasm Metastasis 9%
9. Phase II Clinical Trials 8%
10. Progression-Free Survival 6%
11. Patient Selection 6%
12. Prostate 6%
13. Disease Progression 5%
14. Sensitivity and Specificity 5%